Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $261M (up 30.3% year over year) with net income of $75M.
Q2 2026 key financials · XBRL
- Revenue
- $261M
- +30.3% YoY · +21.3% QoQ
- Net income
- $75M
- +89.6% YoY · +132.2% QoQ
- Operating margin
- 34.2%
- Gross margin
- 75.8%
- EPS (diluted)
- $1.29
- +89.7% YoY · +134.5% QoQ
Source: XBRL data from the Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 10-Q on SEC EDGAR. USD.
Harmony Biosciences Holdings, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $261.3M, up 30.3% YoY from $200.5M, driven by units shipped up 26.5% and 7% pricing
- Gross margin 75.8% vs 81.0% YoY, with cost of product sold 24.2% vs 19.0%
- Operating income $89.3M vs $48.2M; operating margin 34.2% vs 24.0% YoY
- WAKIX strongest product, with average patients on therapy approximately 8,950 and formulary access above 80%
- Pitolisant GR NDA accepted; target PDUFA date April 1, 2027, while BP-205 Phase 1b preparation targets third quarter 2026
Risk Factors
- No risk-factors section provided; submitted text covers Items 2–6 and contains no stated changes from the 10-K
- Debt-default risk under TLA Credit Agreement incorporated by reference to Note 10
- Executive transition risk from Glenn Reicin separation agreement dated July 16, 2026
- Insider-trading compliance risk from Kumar Budur’s terminated and replaced Rule 10b5-1 arrangement
- Potential equity dilution from planned sales of up to 72,406 shares under Budur’s new arrangement
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Harmony Biosciences Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.